These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 25131561)

  • 1. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
    Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
    Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
    Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
    Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
    Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
    Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
    Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
    BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of tumoricidal NK and NK T cell activities by MHC Kb molecules expressed on Th2-type gammadelta T and alphabeta T cells coinfiltrating in early B16 melanoma lesions.
    Seo N; Tokura Y; Furukawa F; Takigawa M
    J Immunol; 1998 Oct; 161(8):4138-45. PubMed ID: 9780186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
    Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
    Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling.
    Martinet L; Jean C; Dietrich G; Fournié JJ; Poupot R
    Biochem Pharmacol; 2010 Sep; 80(6):838-45. PubMed ID: 20470757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures.
    Pont F; Familiades J; Déjean S; Fruchon S; Cendron D; Poupot M; Poupot R; L'faqihi-Olive F; Prade N; Ycart B; Fournié JJ
    Eur J Immunol; 2012 Jan; 42(1):228-40. PubMed ID: 21968650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
    Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
    Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.
    Kajitani K; Tanaka Y; Arihiro K; Kataoka T; Ohdan H
    Breast Cancer Res Treat; 2012 Jul; 134(1):139-55. PubMed ID: 22261932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
    Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
    Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perforin expression can define CD8 positive lymphocyte subsets in pigs allowing phenotypic and functional analysis of natural killer, cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells.
    Denyer MS; Wileman TE; Stirling CM; Zuber B; Takamatsu HH
    Vet Immunol Immunopathol; 2006 Apr; 110(3-4):279-92. PubMed ID: 16325923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.